<DOC>
	<DOCNO>NCT02884713</DOCNO>
	<brief_summary>Helicobacter pylorus ( H. pylorus ) eradication achieve 60-80 % first-line therapy . Different second-line therapeutic option available . However , success second-line therapy address report Saudi Arabia . Objectives The primary objective evaluate efficacy 10-day course levofloxacin , doxycycline esomeprazole non-responders first-line therapy H. pylori eradication Saudi Arabia . Secondary objective include ; symptom response treatment , factor associate eradication H. pylori adverse event associate treatment .</brief_summary>
	<brief_title>Levofloxacin-Doxycycline Helicobacter Pylori Eradication Saudi Arabia</brief_title>
	<detailed_description>A prospective , open-label , single arm study conduct . Patients recruit tertiary care hospital Saudi Arabia June 2013 April 2014 . A total 55 patient previously receive standard triple therapy and/or sequential therapy period 2011 2014 fail eradicate infection . The rescue treatment give ten day consist levofloxacin 500 mg daily , doxycycline 100 mg twice daily , esomeprazole 20 mg twice daily . Urea-breath-test ( UBT ) do minimum 6 week completion treatment confirm H. pylorus eradication . Compliance tolerability regimen also assess .</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>18 year age old Received previous treatment triple therapy , sequential therapy Has evidence persistence H. pylori infection positive urea breath test ( UBT ) , histology rapid urease test ( HP Fast . GI supplyâ„¢ , PA , USA ) Previously treat quadruple levofloxacinbased therapy Had allergy doxycycline , levofloxacin esomeprazole Pregnant lactating Significant hepatic , renal , cardiopulmonary disorder , active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>